User Profile
Select your user profile

VENTANA® PD-L1 (SP263) Assay

US-FDA
IVD For in vitro diagnostic use.
PD-L1 SP263 Assay UC stain image

Guiding immunotherapy decisions

VENTANA PD-L1 (SP263) Assay identifies patients who are most likely to respond to specific therapy, so that you can make informed, efficient treatment decisions that can lead to better clinical outcomes. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.

Empowering pathologists to answer PD-L1 questions

VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying:

 

  • Non-small cell carcinoma (NSCLC) patients eligible for treatment with TECENTRIQ® (atezolizumab)
  • NSCLC patients eligible for treatment with LIBTAYO® (cemiplimab)

 

VENTANA PD-L1 (SP263) Assay further benefits patients by:

 

  • Providing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)*
  • Allowing optimal lung tissue management through PD-L1 testing of archived unstained slides within 12 months

VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemistry assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the programmed death ligand-1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue specimens by light microscopy. The VENTANA PD-L1 (SP263) Assay is used with the OptiView DAB IHC Detection Kit for staining on the BenchMark ULTRA instrument.

NSCLC:

PD-L1 expression in tumor cell (TC) membrane as detected by VENTANA PD-L1 (SP263) Assay in NSCLC is indicated as an aid in identifying patients for treatment with TECENTRIQ® (atezolizumab).

PD-L1 expression in tumor cell (TC) membrane as detected by VENTANA PD-L1 (SP263) Assay in NSCLC is indicated as an aid in identifying patients for treatment with LIBTAYO® (cemiplimab).

Table 1. Therapy and associated indication.

View Full Table

Table 1. Therapy and associated indication.

Indication for use Therapy PD-L1 Expression
NSCLC TECENTRIQ® ≥1 % TC
LIBTAYO® ≥50 % TC
*Please refer to the VENTANA PD-L1 (SP263) Assay method sheet for the full intended use statement and approved therapeutic labeling.

*IC staining with this assay is not used to assess PD-L1 status in NSCLC.

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    Access important product documentation including relevant certificates and other resources.

    After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later